Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Imvaq Therapeutics

Request full access

An innovative cancer immunotherapy company

New York City, United StatesBiotech & Life Sciences

About Imvaq Therapeutics

Imvaq Therapeutics is a clinical-stage biotechnology company focused on developing viral-based immunotherapies for various cancers. Founded in 2018 by CEO Dr. John Choi and researchers from Memorial Sloan Kettering Cancer Center (MSK), the firm is headquartered in New York City. The company's core mission is to engineer and arm immune-stimulating viruses to combat a range of solid tumors, including challenging cancers like triple-negative breast cancer, skin cancers, and sarcoma.

The company's primary technology is its Vaccinia Immunotherapy Platform (VIP)™, which utilizes both oncolytic and non-oncolytic Modified Vaccinia Ankara (MVA) virus strains. A key feature of the VIP platform is its large capacity for transgene insertion, which allows the viruses to be "armed" with multiple immunostimulatory molecules to enhance the anti-tumor response. Imvaq has also developed a proprietary screening process to identify and remove viral genes that suppress the immune system, aiming to increase therapeutic effectiveness. Its lead product candidate, MQ710, is a second-generation immunotherapy based on an armed MVA virus.

Imvaq's business model centers on the research and development of these novel therapies, with the goal of advancing them through clinical trials and eventually to market. The company operates within the competitive immuno-oncology sector, targeting a critical need for more effective treatments for metastatic solid tumors. To finance its operations, Imvaq has successfully raised significant capital. After a Series A round of $10M in July 2017, the company secured a $15 million Series B financing round in September 2020, led by Hanne Capital. This brought its total raised capital to over $25 million, which was earmarked to fund the Investigational New Drug (IND) application and Phase 1 clinical trials for MQ710, as well as to advance other pipeline assets. However, according to some sources, the company's operational status was listed as "Out of Business" as of June 2024.

Source: Dealroom company data

At a glance

Status
Operational
Employees
3
Open positions
None listed
Dealroom signal
15.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Sep 2020 $15M $60M Hanne Capital —
SERIES AEquity / VC Jul 2017 $10M $40M Undisclosed —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Imvaq Therapeutics website traffic

Latest recorded traffic for Imvaq Therapeutics is 270 monthly website visits. Imvaq Therapeutics's team grew 0% over the past year.

Latest monthly visits270 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
TrueBinding (formally Immutics)An early-stage biotherapeutics development company focused on creating new and exciting molecules for applications Foster City, United States Operational 36 $327M $500M
Gemina LabsDeveloped and patented a transformative bio-chemistry that powers next-generation testing platforms for detecting a wide range of pathogens that affect humans and animals Calgary, Canada Operational
Lyopor3D collagen scaffold for 3D cell culture, suitable for testing the behavior of a wide range of cells in their natural 3D environment Brno, Czechia Operational
Evergreen TheragnosticsContract development and manufacturing of therapeutic radiopharmaceuticals Jersey City, United States Acquired
NuGen Medical DevicesAn emerging specialty medical device company focused on developing and commercializing novel drug delivery technologies Toronto, Canada Operational
AC BioscienceA clinical stage biotech company focused on novel approaches to provide more effective treatments for solid tumor cancer patients Ecublens, Switzerland Operational
Sapreme TechnologieDevelops new technologies within the field of macromolecule therapeutics such as antibody-drug conjugates and oligonucleotide-based therapeutics Driebergen-Rijsenburg, Netherlands Operational
CerecinHealthcare company that develops a novel evidence-based therapeutics, and products that aim to help people Denver, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Imvaq Therapeutics in the New York City ecosystem

Live from Dealroom

The Imvaq Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Hanne Capital
Employees 3 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · New York City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Imvaq Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Imvaq Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.